Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

OBJECTIVES: To identify a therapeutic target interval for certolizumab pegol drug levels and examine the influence of anti-drug antibodies in patients with inflammatory joint diseases. METHODS: Certolizumab pegol and anti-drug antibody levels were measured in serum samples collected after 3 months o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gehin, Johanna Elin, Goll, Guro Løvik, Warren, David John, Syversen, Silje Watterdal, Sexton, Joseph, Strand, Eldri Kveine, Kvien, Tore Kristian, Bolstad, Nils, Lie, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883678/
https://www.ncbi.nlm.nih.gov/pubmed/31783773
http://dx.doi.org/10.1186/s13075-019-2009-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883678/
https://www.ncbi.nlm.nih.gov/pubmed/31783773
http://dx.doi.org/10.1186/s13075-019-2009-5

Ejemplares similares